Events
- Join us at Antibody engineering and Therapeutics 2023: Dec 13-16 | December 06, 2023
- CNS Drug Delivery Summit 2023: Biocytogen to Showcase Payload Brain Delivery of Fully Human TFR1 HCAbs | November 30, 2023
- Join us at Cell Bio 2023 by American Society for Cell Biology: Dec 2-6 | November 28, 2023
- $1,000 OFF Any Gene Targeting Project | November 20, 2023
- Check out our poster at 15th Annual PEGS Europe: Nov 14-16 | November 14, 2023
- SITC 2023 Highlights: Biocytogen’s Novel Assets and Products | November 08, 2023
News
- Biocytogen Secures U.S. Patent for Key Technology of the Fully Human Antibody Mouse (RenMab) Platform | December 05, 2023
- Nov 2023 Newsletter | November 16, 2023
- SITC 2023 Highlights: Biocytogen’s Novel Assets and Products | November 08, 2023
- Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti- CD40 mAb) Phase I Trial at ESMO 2023 | October 16, 2023
- Biocytogen Officially Launches RenMice® Series | September 15, 2023
- Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development | September 07, 2023
